Mutation-directed targeted therapy in combination with a PD-L1 inhibitor “is a promising strategy” to extend survival in patients with anaplastic thyroid cancer, according to researchers.

Risk higher for women who gained more than 10 kg weight after 35 years of age versus those with stable weight.

A CXB boost continues to provide an organ preservation benefit at 5 years, though there is some local regrowth after 3 years, researchers found.

Researchers found that the prices of cancer drugs in the US increased post-launch, but there was no such increase for non-cancer drugs.

Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.